
CLRB
Cellectar Biosciences Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
5.290
Open
5.290
VWAP
5.18
Vol
43.07K
Mkt Cap
14.32M
Low
5.150
Amount
223.15K
EV/EBITDA(TTM)
--
Total Shares
35.85M
EV
2.96M
EV/OCF(TTM)
--
P/S(TTM)
--
Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of drugs for treatment of cancer. The Company, through its phospholipid ether drug conjugate (PDC) delivery platform, is focused on developing PDCs that are designed to specifically target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs both independently and through research and development collaborations. Its lead programs are: Iopofosine I 131 (iopofosine), a beta-emitting iodine-131-based program which has been studied extensively; CLR 121225, an actinium-225-based program; and CLR 121125, an iodine-125 Auger-emitting program. Iopofosine evaluation is ongoing in a Phase IIb study in r/r multiple myeloma and central nervous system lymphoma patients and the CLOVER-2 Phase Ib study for pediatric patients with high grade gliomas.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
--
--
-3.700
+1133.33%
--
--
-3.600
-67.57%
--
--
-3.700
+311.11%
Estimates Revision
The market is revising No Change the revenue expectations for Cellectar Biosciences, Inc. (CLRB) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -43.66%.
Revenue Estimates for FY2025
No Change

0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward

-1.28%
In Past 3 Month
Stock Price
Go Down

-43.66%
In Past 3 Month
2 Analyst Rating

-42.75% Downside
Wall Street analysts forecast CLRB stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLRB is 3.00 USD with a low forecast of 3.00 USD and a high forecast of 3.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
1 Hold
0 Sell
Moderate Buy

-42.75% Downside
Current: 5.240

Low
3.00
Averages
3.00
High
3.00

-42.75% Downside
Current: 5.240

Low
3.00
Averages
3.00
High
3.00
Maxim
Buy
to
Hold
downgrade
2025-05-14
Reason
Maxim
Price Target
2025-05-14
downgrade
Buy
to
Hold
Reason
Maxim downgraded Cellectar Biosciences to Hold from Buy. Cellectar's radiopharma pipeline, including the Phase 1-ready assets CLR-121225 and CLR-121125, were the key drivers for Cellectar, but as the company now seeks strategic alternatives for its assets, there is significant uncertainty regarding the future development of these programs, the analyst tells investors in a research note.
Oppenheimer
Jeff Jones
Buy
to
Hold
Downgrades
n/a
2024-12-11
Reason
Oppenheimer
Jeff Jones
Price Target
n/a
2024-12-11
Downgrades
Buy
to
Hold
Reason
Oppenheimer
Jeff Jones
Buy
Maintains
$14 → $12
2024-11-19
Reason
Oppenheimer
Jeff Jones
Price Target
$14 → $12
2024-11-19
Maintains
Buy
Reason
Oppenheimer analyst Jeff Jones lowered the firm's price target on Cellectar Biosciences to $12 from $14 and keeps an Outperform rating on the shares after the company provided Q3 financial and business updates, with updated Iopofosine I131 data in WM being slated for an oral presentation at ASH on December 9th. Management also disclosed that discussions with the FDA around a likely to be required confirmatory trial are anticipated to delay the NDA filing from late Q4 2024 to late Q1 2025. While Oppenheimer remains confident in the ultimate approval, the firm updates its model for actuals, while adjusting timelines and adding a year-end 2024 financing.
Oppenheimer
Jeff Jones
Buy
Reiterates
$14
2024-10-11
Reason
Oppenheimer
Jeff Jones
Price Target
$14
2024-10-11
Reiterates
Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Cellectar Biosciences Inc (CLRB.O) is -0.33, compared to its 5-year average forward P/E of -1.60. For a more detailed relative valuation and DCF analysis to assess Cellectar Biosciences Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-1.60
Current PE
-0.33
Overvalued PE
-0.57
Undervalued PE
-2.64
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
1.26
Current PS
0.00
Overvalued PS
6.30
Undervalued PS
-3.79
Financials
Annual
Quarterly
FY2025Q1
YoY :
-46.67%
-6.40M
Operating Profit
FY2025Q1
YoY :
-75.21%
-6.60M
Net Income after Tax
FY2025Q1
YoY :
-84.21%
-4.30
EPS - Diluted
FY2025Q1
YoY :
-100.00%
N/A
Free Cash Flow
Trading Trends
Insider
Insiders areBuying! The selling amount has increased 1385.12% over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
3
124.8K
USD
Months
3-6
0
0.0
USD
Months
6-9
1
8.4K
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders areBuying! The selling amount has increased 1385.12% over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
3
124.8K
USD
Months
3-6
0
0.0
USD
Months
6-9
1
8.4K
USD
Months
0-12
0
0.0
USD
Months
CLRB News & Events
Events Timeline
2025-07-01 (ET)
2025-07-01
09:27:20
Cellectar prices 865,000 units at $5.00 in underwritten public offering

2025-06-26 (ET)
2025-06-26
09:25:48
Cellectar Biosciences files to sell 755,667 Class A Units

2025-06-26
08:14:12
Cellectar Biosciences, Nusano enter into multi-isotope supply agreement

Sign Up For More Events
Sign Up For More Events
News
8.5
07-02NewsfilterCellectar Biosciences Announces Closing of $6.9 Million Underwritten Public Offering, including Full Exercise of Over-Allotment Option
8.5
07-01NewsfilterCellectar Biosciences Announces Pricing of $6 Million Underwritten Public Offering
5.0
06-30PRnewswireOncology Innovation Just Hit a Turning Point -- Here's What to Watch
Sign Up For More News
People Also Watch

LRHC
La Rosa Holdings
7.950
USD
+0.13%

APDN
Applied DNA Sciences Inc
5.100
USD
-2.86%

JAGX
Jaguar Health Inc
2.300
USD
-0.43%

BCDA
BioCardia Inc
2.310
USD
0.00%

BPT
BP Prudhoe Bay Royalty Trust
0.502
USD
-2.39%

CMCT
Creative Media & Community Trust Corporation
6.850
USD
0.00%

SOS
Sos Ltd
6.850
USD
-3.11%

PSIG
PS International Group Ltd
0.363
USD
0.00%

PEV
Phoenix Motor Inc
0.248
USD
-17.39%

HAO
Haoxi Health Technology Ltd
1.378
USD
-0.14%
FAQ

What is Cellectar Biosciences Inc (CLRB) stock price today?
The current price of CLRB is 5.24 USD — it has decreased -2.06 % in the last trading day.

What is Cellectar Biosciences Inc (CLRB)'s business?

What is the price predicton of CLRB Stock?

What is Cellectar Biosciences Inc (CLRB)'s revenue for the last quarter?

What is Cellectar Biosciences Inc (CLRB)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Cellectar Biosciences Inc (CLRB)'s fundamentals?

How many employees does Cellectar Biosciences Inc (CLRB). have?
